Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Medical Technology

Stevens Creates Leading Neuroscience Innovations and Rehabilitation Devices to Improve Stroke, Spinal Injury and Other Disabilities.

Hoboken, NJ, September 12, 2017 — Thirty three million Americans have a disability that makes it difficult to carry out daily activities, according to the Centers for Disease Control and Prevention.  Those activities run the gamut from simple to complex, grasping a doorknob to walking.

Thankfully there is an increasing availability of rehabilitative devices that can help. From artificial limbs to electrical assisted devices, these solutions are integrating neurobiological technology to offer better control for people who need them.

One new hotbed of development is Stevens Institute of Technology’s Department of Biomedical Engineering, Chemistry and Biological Sciences, where researchers work to develop and improve neurobiological rehabilitation devices every single day. Continue reading

VENDORS EVENT: Somerset County Business Partnership and HINJ to Host ‘How to Do Business with Pharma and Medtech Companies’ on November 2

Bridgewater, NJ, August 6, 2017 — The Somerset County Business Partnership (SCBP) and the HealthCare Institute of New Jersey (HINJ) will host “How to Do Business with Pharma and Medical Technology Companies” on November 2 from 8:00 to 11:30 a.m. at the Raritan Valley Community College, Route 28 and Lamington Road, North Branch.

New Jersey’s biopharmaceutical and medical technology companies purchase more than $6.5 billion worth of goods and services from thousands of local suppliers across the state.

This purchasing power supports more than 350,000 spin-off jobs throughout the state. Continue reading

MedTech Industry Lost Nearly 29,000 Jobs While Device Tax in Effect, U.S. Commerce Reports

Washington, DC, February 9, 2017 — The U.S. medical technology industry saw its jobs ranks fall by nearly 29,000 while the medical device excise tax was in effect, according to the latest figures from the U.S. Department of Commerce.

Specifically, from 2012 to 2015, the number of U.S. medtech jobs declined from 401,472 to 372,638 – a loss of 28,834 jobs or a 7.2 percent decrease for the time period.

“These numbers reveal just how devastating of an impact the device tax had on our industry and underscore the urgent need for permanent repeal,” said Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed). Continue reading

AdvaMed Survey Data Shows MedTech Industry Poised for Greater Investment and Growth with Full Device Tax Repeal

medical-device-tax-23Washington, DC, January 12, 2017 — Medical technology companies are leveraging the 2015 suspension of the medical device excise tax to expand their businesses and investments, according to a new survey from the Advanced Medical Technology Association (AdvaMed).

The study explored various impacts from the tax’s suspension — from job retention and creation to elevated R&D infusions — and suggests a broad range of strong economic activity. Industry analysts believe, however, greater economic growth would occur with permanent device tax repeal.

“Our members are bullish on future industry growth and job creation, as these numbers indicate,” said AdvaMed President and CEO Scott Whitaker. Continue reading

AdvaMed’s MedTech Conference Honors Green Sun Medical as 2016 MedTech Innovator Winner

advamed-logo-croppedWashington, DC, November 8, 2016 — AdvaMed 2016: The MedTech Conference, the leading event for medical technology professionals in North America, and MedTech Innovator named Green Sun Medical the first place winner of the global competition and awarded the company a $200,000 cash prize.

The honor was announced during the Advanced Medical Technology Association’s (AdvaMed) 2016 MedTech Conference, which was held October 17-19 in Minneapolis, MN.

Held in partnership with AdvaMed Accel, MedTech Innovator is the medtech industry’s global competition and virtual accelerator that identifies and accelerates the development of transformative innovations. Continue reading

Vendors Event: Morris Co. Chamber and HINJ to Host ‘How to Do Business with Pharma and Medtech Companies’ November 1


Florham Park, NJ, October 28, 2016 — The HealthCare Institute of New Jersey (HINJ) is partnering with the Morris County Chamber of Commerce on a breakfast meeting for its members on “How to Do Business with Pharma and Medical Technology Companies on Tuesday, November 1.

The program will be moderated by HINJ President and CEO Dean Paranicas and will feature procurement executives from Pfizer and Celgene.

The event will be held from 8:30 to 10:00 a.m. at the College of St. Elizabeth at 2 Convent Road, Morristown.

To register, click below.

AdvaMed Recommits to Fostering Early-State Innovation; New Report Highlights Challenges to Medtech Entrepreneurship

advamed-logo-croppedWashington, DC, October 25, 2016 — The Advanced Medical Technology Association (AdvaMed) on October 17 affirmed its commitment to advancing a comprehensive set of policy objectives to invigorate the innovation ecosystem for early-stage device and diagnostics companies.

A new report — “A Future at Risk:  Economic Performance, Entrepreneurship, and Venture Capital in the U.S, Medical Technology Sector” — released at the association’s annual meeting, outlines significant warning signs that, if left unaddressed, could hamper long-term growth and entrepreneurship.

Some key signals identified in the report, based on a number of independent sources on medtech industry trends, include: Continue reading

HINJ’s ‘Value of Medical Innovation’ Portal Showcases How Life Sciences Is Saving Money — And Lives

Doctor researcher numbersNew Brunswick, NJ, August 5, 2016 ― The HealthCare Institute of New Jersey (HINJ) continues to update its Value of Medical Innovation, a fact-driven, consumer-friendly digital library that delves into the myriad benefits of research-driven medical innovation, which saves money — and saves lives.

HINJ’s Value of Medical Innovation presents statistics from a number of resources, including the Advanced Medical Technology Association (AdvaMed), the Biotechnology Organization (BIO), the Pharmaceutical Research and Manufacturers of America (PhRMA), U.S. government sources and various medical research organizations.

The Value of Medical Innovation page is the latest offering on HINJ.org, which was launched in February 2013 as part of HINJ’s strategic plan to build a dynamic communications capability that delivers relevant, robust and timely information to internal and external stakeholders. Continue reading

Stevens Center for Healthcare Innovation Helps Tackle Social Needs in Medical Technology Development

Stevens Institute of TechnologyHoboken, NJ, July 19, 2016 ― A significant gift from an alumnus will serve as a powerful growth engine for the three-year-old Center for Healthcare Innovation at Stevens Institute of Technology in Hoboken, New Jersey.

Created in 2013 as a vehicle to improve medical technology and healthcare delivery, the Stevens Center for Healthcare Innovation intersects the fields of medicine, engineering and science by sponsoring research, building partnerships, commercializing intellectual property and creating curricula to strengthen skill gaps in the workforce.

Today, more than 60 university faculty from diverse academic disciplines are affiliated with the Center for Healthcare Innovation, tackling unmet needs in medical technology and major issues. Continue reading

NIH Panel Approves First Test of CRISPR Editing in Humans; Study to Target Three Types of Cancer

Gene editing crisprBethesda, MD, June 22, 2016The Washington Post reports that a National Institutes of Health (NIH) advisory panel yesterday approved the first human use of the gene-editing technology CRISPR, for a study designed to target three types of cancer and funded by tech billionaire Sean Parker’s new cancer institute.

The experiment, proposed by researchers at the University of Pennsylvania, would use CRISPR-Cas9 technology to modify patients’ own T cells to make them more effective in attacking melanoma, multiple myeloma and sarcoma.

The federal Recombinant DNA Advisory Committee approved the Penn proposal unanimously, with one member abstaining.  The experiment still must be approved by the Food and Drug Administration, which regulates clinical trials. Continue reading